PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: puretechhealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $58.00 → $45.00 | Outperform | Leerink Partners |
| 1/7/2022 | $76.00 → $70.00 | Outperform | SVB Leerink |
| 8/25/2021 | $74.00 → $76.00 | Outperform | SVB Leerink |
Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously
SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously
SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeut
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, includ
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Strategic healthcare leader brings more than 30 years of global experience to PureTech's Board following notable positions with Cardinal Health, Teva Pharmaceuticals and McKinsey & Company PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Michele Holcomb, PhD, will join its board of directors as an independent non-executive director. Dr. Holcomb's appointment will take effect as of September 23, 2024. She brings more than 30 years of expertise leading global healthcare companies through strategic inflection points and preparing in
Prominent pharmaceutical leader from AstraZeneca, Abbott, GlaxoSmithKline and Eli Lilly, brings extensive regulatory affairs and clinical development expertise to Seaport Board PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of David Wheadon, M.D., to its Board of Directors. Dr. Wheadon is a physician and psychiatrist with more than three decades of experience in regulatory affairs, clinical strategy, and global health polic
Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity, Vedanta Biosciences, a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases, today announced three appointments to its leadership team. Christof Marré, a seasoned biopharma marketing leader, joins the company as Senior Vice President and Head of Commercial. In add
Antony Loebel, M.D., CNS drug development expert and former CEO and CMO at Sunovion Pharmaceuticals, appointed as Seaport's Chief Medical Officer and President of Clinical Development Lana Gladstein, J.D., experienced attorney across all legal matters, including corporate governance, M&A transactions, alliance management and intellectual property, joins Seaport as General Counsel PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced it has expa
VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection (CDI) PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study of VE303, which is an orally administered defined bacterial consortium candidate that is being developed for the pre
Denice Torres, J.D., former Board Member of Karuna Therapeutics and accomplished healthcare executive at Johnson & Johnson, Janssen Neuroscience and Eli Lilly, appointed to Seaport Board of Directors Eric Green, MBA, former development and commercialization leader at Alnylam Pharmaceuticals, joins Seaport as Chief Operating Officer Michael Chen, Ph.D., Co-Founder of Seaport and former Head of Innovation at PureTech Health named Seaport Chief Scientific Officer PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, a biopharmaceutical company that is charting a proven p
SC 13G - PureTech Health plc (0001782999) (Subject)
SC 13G/A - PureTech Health plc (0001782999) (Subject)
SC 13G/A - PureTech Health plc (0001782999) (Subject)
SC 13G/A - PureTech Health plc (0001782999) (Subject)
SC 13G - PureTech Health plc (0001782999) (Subject)
SC 13D/A - PureTech Health plc (0001782999) (Filed by)